Skip to main content
. Author manuscript; available in PMC: 2021 Apr 19.
Published in final edited form as: J Pediatr Gastroenterol Nutr. 2021 Feb 1;72(2):324–340. doi: 10.1097/MPG.0000000000003001

TABLE 2.

Summary of recommendations

Category Recommendation Grade
Nutrition and endocrine 1. Patients with CP are at risk for macro- and micronutrient deficiencies. Patients should be monitored for growth and pubertal delay, dietary intake, and fat-soluble vitamin deficiencies. Growth and intake should be reviewed at every clinic visit, a minimum of every 6 to 12 months. Fat-soluble vitamin laboratory analysis should occur every 12 to 18 months or as clinically indicated 1B
2. A multidisciplinary approach that includes a clinical pediatric dietitian is needed to adequately monitor nutritional status, evaluate nutrient intake and provide education and recommendations to help prevent both malnutrition and obesity 1C
3. There is a clear role for PERT in children with CP who have EPI with steatorrhea, poor growth and/or nutritional deficiencies. PERT dosing for CP-associated EPI is similar to that used in patients with CF 1B
4. Children with CP should be screened yearly for pancreatogenic DM with a fasting glucose and HbA1c level 1C
5. Consider OGTT if pre-diabetes is present based on abnormal fasting glucose (100–125mg/dL) and/or HbA1c level (5.7%–6.4%). OGTT should be performed annually once a patient is considered to have pre-diabetes 1C
6. Chronic pancreatitis patients with diabetes should be referred to a pediatric endocrinologist to optimize glucose management and determine if evaluation for other forms of DM should be considered 1B
7. It is important to address clinical symptoms of malabsorption and PERT in children with CP and DM to improve glycemic control 1C
8. Insufficient data exists to recommend the use of antioxidants as a treatment to prevent EPI or other disease progression in children with CP 2C
Pain management 9. Treatment of pain in pediatric CP requires a multidisciplinary approach, ideally involving a pediatric pain physician, pediatric gastroenterologist, psychologist, nurse, and physical therapist 1B
10. Cognitive behavioral Therapy (CBT) should be considered in management of pediatric CP pain 1B
11. Physical therapy may be considered as an adjunct therapy for pain management in children with CP 2B
12. There is insufficient data to recommend PERT as therapy for pain in children without EPI 1B
13. There is insufficient data to recommend antioxidants, steroids, leukotriene antagonists, or somatostatins in the management of pain for children with CP 2C
14. Analgesic pain management in CP should follow an “analgesic ladder” that incorporates the layering of non-opioid and opioid medications. Ideally this should be directed by a pain specialist working in partnership with a pancreatologist or gastroenterologist 1B
15. Neuromodulators may be effective in treating pain in children with CP as part of a multidisciplinary approach 1C
16. Celiac plexus block for pain has not been shown to be effective in children with CP and cannot be recommended 1C
17. Children with CP suffering from pain refractory to standard medical management should be evaluated at a center with pediatric experience in pain management 1C
Lifestyle modifications 18. On the basis of long-term adult data, providers should caution patients about the acute and chronic negative effects of alcohol abuse on pancreatic health 1B
19. Health-care providers should caution patients about the dose-dependent response of tobacco smoking on the development and progression of CP among adult patients and should advise against smoking 1A
20. Data are limited regarding the impact of weight and BMI on CP outcomes, as such, providers should counsel patients and parents about a balanced healthy diet and lifestyle 1C
21. Administering a survey tool to assess QOL and/or functional assessment among pediatric patients to assess degree of impairment and drive targeted interventions indicated 2C
Sequelae of disease 22. The majority of pancreatic fluid collections will resolve spontaneously with supportive care. Intervention is reserved for complications from mass-effect, infection/necrosis or if spontaneous regression of the collection is thought to be unlikely 1B
23. Children with CP that continue to exhibit abdominal pain, bloating or other GI concerns deserve an appropriate GI workup to evaluate for other etiologies that may explain their symptoms 1C

CP = chronic pancreatitis; DM = diabetes mellitus; EPI = exocrine pancreatic insufficiency; GI = gastrointestinal, OGTT = oral glucose tolerance test; PERT = pancreatic enzyme replacement therapy; QOL = quality of life.